Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 8/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 8/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 6/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15844843 | 1.00 | PIM1 (0.45) | PIM1PIM2PIM3HTR6BRD4 | |
| SCHEMBL12614856 | 0.92 | PIM1 (0.47) | PIM1PIM2PIM3USP30S1PR1 | |
| SCHEMBL9904582 | 0.82 | CTPS1 (0.38) | PIM1PIM2HTR6BRD4BCHE | |
| SCHEMBL9904579 | 0.82 | CTPS1 (0.38) | PIM1PIM2HTR6BRD4BCHE | |
| SCHEMBL15844797 | 0.82 | PIM1 (0.47) | PIM1PIM2PIM3 | |
| SCHEMBL15844554 | 0.82 | PIM1 (0.47) | PIM1PIM2PIM3 | |
| SCHEMBL12615728 | 0.82 | PIM1 (0.47) | PIM1PIM2PIM3 | |
| SCHEMBL15854689 | 0.79 | PIM1 (0.45) | PIM1PIM2PIM3USP30S1PR1 | |
| SCHEMBL15854675 | 0.79 | PIM1 (0.45) | PIM1PIM2PIM3USP30S1PR1 | |
| SCHEMBL12615970 | 0.79 | PIM1 (0.51) | PIM1PIM2PIM3HTR6S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321756-B2 | Azole compounds as PIM inhibitors | AMGEN INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | AMGEM INC. (US) | 2014-07-03 | — | — | US | disclosed |
| EP-2688886-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| WO-2012129338-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | PIM1, PIM3, PIM2 | PIM1 1/4885PIM2 3/4885PIM3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.